Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Chattem explores homeopathy

This article was originally published in The Tan Sheet

Executive Summary

Firm "is working to develop alternate formulations for Sportscreme and Aspercreme" in case FDA does not look favorably on available clinical data for active ingredient trolamine salicylate, Chattem says in recent 10-K filing. Firm also states it could market the pain relief products as homeopathic agents, or submit new studies on ingredient's safety and efficacy. In May 2001, FDA recommended Chattem adjust the protocol for a proposed study to more accurately reflect the actual use of topical analgesics (1"The Tan Sheet" May 7, 2001, p. 4)...

You may also be interested in...

Chattem Trolamine Salicylate Arthritis, Muscle Pain Studies Urged By FDA

Chattem should consider allowing study subjects to apply 10% trolamine salicylate cream to any painful joints or muscles, although efficacy studies could focus only on a single joint or muscle, FDA Division of OTC Drug Products Director Charles Ganley, MD, said at a May 1 feedback meeting.

Medicines Must Be Designated As Priority Items, Says IGBA

Governments around the world should designate all medicines as ‘priority essential products’, the IGBA has urged, as a surge in demand coinciding with a reduction in the number of flights and rising freight costs are making it more difficult for suppliers to meet global requirements amid the coronavirus pandemic.

COVID-19: FDA Will Hold Remote Meetings With Firms, Extends Marketing Application Due Dates

In a letter to the medtech industry, the FDA’s William Maisel says the US agency will hold remote meetings with device makers and other stakeholders through the end of May. The FDA also extended due dates for marketing applications by 90 days.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts